Current Status of Percutaneous PFO Closure

  • N. Rohrhoff
  • J. P. Vavalle
  • S. Halim
  • T. L. Kiefer
  • J. K. Harrison
Interventional Cardiology (S Rao, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Interventional Cardiology


The clinical significance of persistent patent foramen ovale (PFO) is not well defined. Empirically, PFO has been associated with many clinical conditions. In cryptogenic stroke, migraine, and orthodeoxia/platypnea, a plausible biologic mechanism exists to support PFO closure as a possible treatment. Although transcatheter closure of PFO has been available for over 2 decades, it has remained controversial due to a paucity of evidence to guide patient and device selection. Contemporary studies investigating PFO closure as treatment for patients with these conditions have been published recently and longitudinal data regarding the safety and efficacy of the devices is now available. In this review, we aim to describe the potential clinical significance of a patent foramen in the adult, appraise the newest additions to the body of evidence, and discuss the safety, benefit, patient selection, and future of transcatheter treatment of PFO.


Patent foramen ovale PFO Cryptogenic stroke Migraine headache Percutaneous closure 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59:17–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Sadler TW. Langman’s Medical Embryology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 1990.Google Scholar
  3. 3.
    Sacco RL et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla VG. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology. 1999;52:1622–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilmshurst P, Nightingale S. Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin Sci. 2001;100:215–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Toffart AC, Bouvaist H, Feral V, Blin D, Pison C. Hypoxemia-orthodeoxia related to patent foramen ovale without pulmonary hypertension. Heart Lung. 2008;37:385–9.PubMedCrossRefGoogle Scholar
  7. 7.••
    Furlan AJ, Reisman M, Massaro J, et al. On behalf of the CLOSURE I Investigators. Closure or medical therapy of cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991–9. This was a randomized-controlled trial directly addressing the benefit of PFO closure and resulted in identification of safety and effectiveness issues that led to a discontinuation of the CardioSEAL Starflex device.PubMedCrossRefGoogle Scholar
  8. 8.••
    Carroll JD, Saver JL, Thaler DE, et al. On behalf of the RESPECT investigators. Closure of patent foramen ovale vs medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092–100. In the as-treated analysis of this randomized-controlled trial, Amplatzer device treatment was found to be superior to medical therapy in the prevention of recurrent ischemic stroke.PubMedCrossRefGoogle Scholar
  9. 9.••
    Meier B, Kalesan B, Mattle HP, et al. On behalf of the PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368:1083–91. This is the first randomized-controlled trial directly addressing the clinical question.PubMedCrossRefGoogle Scholar
  10. 10.••
    Dowson A, Mulllen MJ, Peatfield R, Muir K, Khan A, Wells C, et al. Migraine intervention with STARFlex Technology trial. A prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex Septal Repair Implant to resolve refractory migraine headache. Circulation. 2008;117:1397–404. This is the only randomized-controlled trial that explores the benefit and safety of transcatheter PFO closures as treatment for an indication other than cryptogenic stroke.PubMedCrossRefGoogle Scholar
  11. 11.•
    Fenster BE, Nguyen BH, Buckner JK, Freeman AM, Carroll JD. Effectiveness of percutaneous closure of patent foramen ovale for hypoxemia. Am J Cardiol. 2013;112(8):1258–62. This study evaluated 97 patients with systemic hypoxemia that underwent PFO device treatment and found statistically significant clinical success was achieved in 70% of the patients.PubMedCrossRefGoogle Scholar
  12. 12.
    Cheng TO. Mechanisms of platypnea-orthodeoxia: what causes water to flow uphill? Circulation. 2002;105:e47.PubMedCrossRefGoogle Scholar
  13. 13.
    Meissner I, Whisnant JP, Khandheria BK, Spittell PC, O’Fallon WM, Pascoe RD, et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Mayo Clin Proc. 1999;74:862–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006;47:440–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Di Tullio MR, Sacco RL, Sciacca RR, Jin Z, Homma S. Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol. 2007;49:797–802.PubMedCrossRefGoogle Scholar
  16. 16.
    Kizter JR, Devereux RB. Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med. 2005;353:2361–72.CrossRefGoogle Scholar
  17. 17.
    Mugge A, Daniel WG, Angermann C, Spes C, Khandheria BK, Kronzon I, et al. Atrial septal aneurysm in adult patients. A multicenter study using transthoracic and transesophageal echocardiography. Circulation. 1995;91:2785–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Hanley PC, Tajik AJ, Hynes JK, Edwards WD, Reeder GS, Hagler DJ, et al. Diagnosis and classification of atrial septal aneurysm by two-dimensional echocardiography: report of 80 consecutive cases. J Am Coll Cardiol. 1985;6:1370–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Schneider B, Hanrath P, Vogel P, Meinertz T. Improved morphologic characterization of atrial septal aneurysm by transesophageal echocardiography: relation to cerebrovascular events. J Am Coll Cardiol. 1990;16:1000–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Zabalgoitia-Reyes M, Herrera C, Gandhi DK, Mehlman DJ, McPherson DD, Talano JV. A possible mechanism for neurologic ischemic events in patients with atrial septal aneurysm. Am J Cardiol. 1990;66:761–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Pearson AC, Nagelhout D, Castello R, Gomez CR, Labovitz AJ. Atrial septal aneurysm and stroke: a transesophageal echocardiographic study. J Am Coll Cardiol. 1991;18:1223–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Silver MD, Dorsey JS. Aneurysms of the septum primum in adults. Arch Pathol Lab Med. 1978;102:62–5.PubMedGoogle Scholar
  23. 23.
    Mattioli AV, Bonetti L, Aquilina M, Oldani A, Longhini C, Mattioli G. Association between atrial septal aneurysm and patent foramen ovale in young patients with recent stroke and normal carotid arteries. Cerebrovac Dis. 2003;15:4–10.CrossRefGoogle Scholar
  24. 24.
    Burger AJ, Jadhav P, Kamalesh M. Low incidence of cerebrovascular events in patients with incidental atrial septal aneurysm. Echocardiography. 1997;14:589–96.PubMedCrossRefGoogle Scholar
  25. 25.
    Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Atrial anatomy in noncardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol. 2003;42:1066–72.PubMedCrossRefGoogle Scholar
  26. 26.
    Pinto FJ. When and how to diagnose patent foramen ovale. Heart. 2005;91:438–40.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Pearson AC, Labovitz AJ, Tatineni S, Gomez CR. Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. J Am Coll Cardiol. 1991;17:66–72.PubMedCrossRefGoogle Scholar
  28. 28.
    Teague SM, Sharma MK. Detection of paradoxical cerebral echo contrast embolization by transcranial Doppler ultrasound. Stroke. 1991;22:740–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Schneider B, Zienkiewicz T, Jansen V, Hofmann T, Noltenius H, Meinertz T. Diagnosis of patent foramen ovale by transesophageal echocardiography and correlation with autopsy findings. Am J Cardiol. 1996;77:1202–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Falk V, Walther T, Krankenberg H, Mohr FW. Trapped thrombus in a patent foramen ovale. Thorac Cardiovasc Surg. 1997;45:90–2.PubMedCrossRefGoogle Scholar
  31. 31.
    Koullias GJ, Elefteriades JA, Wu I, Jovin I, Jadbabaie F, McNamara R. Massive paradoxical embolism: caught in the act. Circulation. 2004;109:3056–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Fukumoto A, Yaku H, Doi K, et al. Continuous thrombus in the right and left atria penetrating the patent foramen ovalis. Circulation. 2005;112:e143–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Doufekias E, Segal AZ, Kizer JR. Cardiogenic and aortogenic brain embolism. J Am Coll Cardiol. 2008;51:1049–59.PubMedCrossRefGoogle Scholar
  34. 34.
    Mascarenhas V, Kalyanasundaram A, Nassef LA, Lico S, Qureshi A. Simultaneous massive pulmonary embolism and impending paradoxical embolism through a patent foramen ovale. J Am Coll Cardiol. 2009;53:1338.PubMedCrossRefGoogle Scholar
  35. 35.
    Steiner MM, Di Tullio MR, Rundek T, Gan R, Chen X, Liguori C, et al. Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke. 1998;29:944–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Webster MW, Chancellor AM, Smith HG, Swift DL, Sharpe DN, Bass NM, et al. Patent foramen ovale in young stroke patients. Lancet. 1988;2:11–2.PubMedCrossRefGoogle Scholar
  37. 37.
    Lechat P, Mas JL, Lascault G, Loron P, Theard M, Klimczac M, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;318:1148–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Fisher DC, Fisher EA, Budd JH, Rosen SE, Goldman ME. The incidence of patent foramen ovale in 1000 consecutive patients. A contrast transesophageal echocardiography study. Chest. 1995;107:1504–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Job FP, Ringelstein EB, Grafen Y, Flachskampf FA, Doherty C, Stockmanns A, et al. Comparison of transcranial contrast Doppler sonography and transesophageal contrast echocardiography for the detecting of patent foramen ovale in young stroke patients. Am J Cardiol. 1994;74:381–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Mas JL, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm or both. N Engl J Med. 2001;345:1740–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology. 2000;55:1172–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A. Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med. 2007;357:2262–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625–31.PubMedCrossRefGoogle Scholar
  44. 44.
    Homma S, Di Tullio MR, Sacco RL, Mihalatos D, Li Mandri G, Mohr JP. Characteristics of patent foramen ovale associated with cryptogenic stroke: a biplane transesophageal echocardiographic study. Stroke. 1994;25:582–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Hausmann D, Mügge A, Daniel WG. Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol. 1995;26:1030–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Ozdemir AO, Tamayo A, Munoz C, Dias B, Spence JD. Cryptogenic stroke and patent foramen ovale: clinical clues to paradoxical embolism. J Neurol Sci. 2008;275:121–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Kent DM, Trikalinos TA, Thaler DE. Patent foramen ovale and cryptogenic stroke. N Engl J Med. 2008;358:1519–20.PubMedGoogle Scholar
  48. 48.
    Kent DM, Thaler DE. Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke. 2010;42(Suppl):S26–30.CrossRefGoogle Scholar
  49. 49.
    Mas JL, Zuber M. Recurrent cerebrovascular events in patients with patent foramen ovale, atrial septal aneurysm, or both and cryptogenic stroke or transient ischemic attack. Am Heart J. 1995;130:1083–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Bogousslavsky J, Garazi S, Jeanrenaud X, Aebischer N, Van Melle G. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Neurology. 1996;46:1301–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Cabanes L, Mas JL, Cohen A, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age: a study using transesophageal echocardiography. Stroke. 1993;24:1865–73.PubMedCrossRefGoogle Scholar
  52. 52.
    Wilmshurst P, Nightingale S. The role of cardiac and pulmonary pathology in migraine: a hypothesis. Headache. 2006;46:429–34.PubMedCrossRefGoogle Scholar
  53. 53.
    Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic or transient ischemic attack: a statement for healthcare professionals from the American Heart. Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology. affirms the value of this guideline. Stroke. 2006;37:577–617.PubMedCrossRefGoogle Scholar
  54. 54.
    Rengifo-Moreno P, Palacios IF, Junpaparp P, Witzke CF, Morris DL, Romero-Corral A. Patent foramen ovale vs transcatheter closure vs medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2013;34(43):3342–52.PubMedCrossRefGoogle Scholar
  55. 55.
    Martin F, Sanchez PL, Doherty E, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation. 2002;106:1121–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Meier B. Closure of patent foramen ovale: technique, pitfalls, complications and follow-up. Heart. 2005;91:444–8.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Krasuski RA, Hart SA, Allen D, et al. Prevalence and repair of intra-operatively diagnosed patent foramen ovale and association with perioperative outcomes and long-term survival. JAMA. 2009;302:290–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Devuyst G, Bogousslavasky J, Ruchat P, et al. Prognosis after stroke followed by surgical closure of patent foramen ovale: a prospective follow-up study with brain MRI and simultaneous transesophageal and transcranial Doppler ultrasound. Neurology. 1996;47:1162–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Fischer D, Fuchs M, Schaefer A, et al. Transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Procedural and follow-up results after implantation of the StarFlex occlude device with conjunctive intensified anticoagulation regimen. J Interv Cardiol. 2008;21:183–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Von Bardeleben RS, Richter C, Otto J, et al. Long term follow-up after percutaneous closure of PFO in 357 patients with paradoxical embolism: difference in occlusion systems and influence of atrial septum aneurysm. Int J Cardiol. 2009;134:33–41.CrossRefGoogle Scholar
  61. 61.
    Taaffe M, Fischer E, Baranowski A, et al. Comparison of three patent foramen ovale closure devices in a randomized trial (Amplatzer vs CardioSEAL—STARFlex vs Helex occluder). Am J Cardiol. 2008;101:1353–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Krumsdor U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1000 consecutive patients. J Am Coll Cardiol. 2004;43:302–9.CrossRefGoogle Scholar
  63. 63.
    Anzai H, Child J, Natterson B, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol. 2004;93:426–31.PubMedCrossRefGoogle Scholar
  64. 64.
    Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand W, Kleinman CS. PFO closure complications from the AGA registry. Catheter Cardiovasc Interv. 2008;72:74–9.PubMedGoogle Scholar
  65. 65.
    Staubach S, Steinberg DH, Zimmermann W, et al. New onset atrial fibrillation after patent foramen ovale closure. Catheter Cardiovasc Interv. 2009;74:889–95.PubMedCrossRefGoogle Scholar
  66. 66.
    Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices in 1000 consecutive patients. J Am Coll Cardiol. 2004;53:302–9.CrossRefGoogle Scholar
  67. 67.
  68. 68.
  69. 69.
    Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Peri-procedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J. 2004;25:424–30.PubMedCrossRefGoogle Scholar
  70. 70.•
    Hornung M, Bertog SC, Franke J, Id D, Taaffe M, Wunderlich N, et al. Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. Eur Heart J. 2013;34(43):3362–9. This study provided long-term safety and efficacy information regarding commonly used devices for PFO treatment.PubMedCrossRefGoogle Scholar
  71. 71.
    Silvestry FE, Naseer N, Wiegers SE, Hirshfield Jr JW, Hermann HC. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occlude. Catheter Cardiovasc Interv. 2008;71:383–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Thaler DE, Saver JL, Smalling RW, et al. Effect of having an Amplatzer Patent foramen occlusion device in place in the RESPECT Trial. 2013 European Stroke Conference; May 30, 2013; London, UK. Large Clinical Trials B; 2Google Scholar
  73. 73.
    Steinberg DH, Staubach S, Franke J, Sievert H. Defining structural heart disease in the adult patient: current scope, inherent challenges and future directions. Eur Heart J. 2010;12(Suppl E):E2–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • N. Rohrhoff
    • 1
  • J. P. Vavalle
    • 1
  • S. Halim
    • 1
  • T. L. Kiefer
    • 1
  • J. K. Harrison
    • 1
  1. 1.Duke University Medical CenterDurhamUSA

Personalised recommendations